In recent years, combination therapy with lenvatinib, PD-1/PD-L1 antibody, and FOLFOX-HAIC demonstrated significant efficacy in advanced HCC, which not only showed an improved objective response rate (ORR), but also significantly prolonged patient survival (20). The gene discussed is CD274; the disease is hepatocellular carcinoma.